Skip to Main content Skip to Navigation
Journal articles

Blockade of HVEM for Prostate Cancer Immunotherapy in Humanized Mice

Abstract : The herpes virus entry mediator (HVEM) delivers a negative signal to T cells mainly through the B and T lymphocyte attenuator (BTLA) molecule. Thus, HVEM/BTLA may represent a novel immune checkpoint during an anti-tumor immune response. However, a formal demonstration that HVEM can represent a target for cancer immunotherapy is still lacking. Here, we first showed that HVEM and BTLA mRNA expression levels were associated with a worse progression-free interval in patients with prostate adenocarcinomas, indicating a detrimental role for the HVEM/BTLA immune checkpoint during prostate cancer progression. We then showed that administration of a monoclonal antibody to human HVEM resulted in a twofold reduction in the growth of a prostate cancer cell line in NOD.SCID.gc-null mice reconstituted with human T cells. Using CRISPR/Cas9, we showed that the therapeutic effect of the mAb depended on HVEM expression by the tumor, with no effect on graft vs. host disease or activation of human T cells in the spleen. In contrast, the proliferation and number of tumor-infiltrating leukocytes increased following treatment, and depletion of CD8+ T cells partly alleviated treatment’s efficacy. The expression of genes belonging to various T cell activation pathways was enriched in tumor-infiltrating leukocytes, whereas genes associated with immuno-suppressive pathways were decreased, possibly resulting in modifications of leukocyte adhesion and motility. Finally, we developed a simple in vivo assay in humanized mice to directly demonstrate that HVEM expressed by the tumor is an immune checkpoint for T cell-mediated tumor control. Our results show that targeting HVEM is a promising strategy for prostate cancer immunotherapy.
Document type :
Journal articles
Complete list of metadata

https://www.hal.inserm.fr/inserm-03272263
Contributor : Gilles Marodon Connect in order to contact the contributor
Submitted on : Monday, June 28, 2021 - 11:24:52 AM
Last modification on : Friday, July 1, 2022 - 3:37:22 AM
Long-term archiving on: : Wednesday, September 29, 2021 - 6:55:53 PM

File

cancers-13-03009.pdf
Publisher files allowed on an open archive

Identifiers

Citation

Nicolas Aubert, Simon Brunel, Daniel Olive, Gilles Marodon. Blockade of HVEM for Prostate Cancer Immunotherapy in Humanized Mice. Cancers, MDPI, 2021, 13 (12), pp.3009. ⟨10.3390/cancers13123009⟩. ⟨inserm-03272263⟩

Share

Metrics

Record views

39

Files downloads

46